Sarepta Therapeutics' current valuation is not reflecting the company's FY17 guidance for Exondys 51 and long-term data on slowing progression of Duchenne muscular dystrophy, Oppenheimer analyst Hartaj Singh tells investors in a research note. If an acquirer were to target Sarepta, recent biotech deals imply that the company "would be a bargain" just on Exondys 51 worldwide sales potential of $750M and without other exon mutations, the analyst contends. Singh notes the shares are currently trading at a 50%-75% discount to recent takeouts in the biotech space, namely Actelion, Ariad and Medivation. He keeps an Outperform rating on Sarepta with a $76 price target. The stock closed yesterday down 10c to $31.40.